ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis Regimen Among People Living with HIV
Retrieved on:
Wednesday, February 14, 2024
Infection, Bangladesh Technical Education Board, Tuberculosis, NIAID, Blood, Safety, ACTG, Trial of the century, TB, Risk, University, ART, Rifapentine, University of London, University of California, Johns Hopkins University, UM1, Pharmacokinetics, Diagnosis, Ageing, HIV, Research, University of North Carolina, Pharmaceutical industry
Previously, ACTG study A5349 demonstrated that a four-month, four-drug TB regimen that included high-dose rifapentine was as effective as the standard six-month regimen, cutting the treatment time by one third.
Key Points:
- Previously, ACTG study A5349 demonstrated that a four-month, four-drug TB regimen that included high-dose rifapentine was as effective as the standard six-month regimen, cutting the treatment time by one third.
- “Understanding the relationship between these anti-TB and HIV medications is crucial, as an estimated one third of people living with HIV worldwide are at risk for developing TB,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
- Dolutegravir is being supplied to study A5406 by ViiV Healthcare Ltd and the fixed-dose combination of dolutegravir/tenofovir disoproxil fumarate/lamivudine is being supplied by Viatris.
- The ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice Chair).